Skip to main content

Updated from 8:38 a.m. EST


( MOT) caught a bid Thursday morning after Deutsche Bank raised its investment rating on the stock to buy from hold. Shares added 11 cents to $15.4o Thursday morning after the brokerage praised the company's new handset line and said recent channel checks were encouraging. Motorola unveiled a new line of 3G cell phones at a conference in Germany earlier Thursday. The stock is down 11% since the start of the year.


( RETK) eased Thursday morning after suitor


(SAP) - Get Free Report

said it was waiting for a Retek statement before announcing its next move. SAP lost frontrunner status in the battle for Retek, a provider of retail-industry software, when


(ORCL) - Get Free Report

said Tuesday it wanted to buy the company for $9 a share. SAP had previously bid was $8.50. "Retek now has to get in touch with us," SAP CEO Henning Kagermann told the


. Retek fell 3 cents to $10.60.

Martek Biosciences

( MATK) said first-quarter earnings were $7.1 million, or 23 cents a share, on revenue of $66.5 million, matching estimates. But company executives previewed a second-quarter sales shortfall on a conference call, saying revenue will be about $55 million. Analysts surveyed by Thomson First Call had been forecasting revenue of about $73 million in the period. The stock has run up about 27% from the start of the year and closed Wednesday at $65.18. It fell $5.18 to $60 Thursday morning.

Following rival


(XLNX) - Get Free Report

lead, semiconductor company


(ALTR) - Get Free Report

Wednesday night raised its estimate of first-quarter revenue. The company expects first-quarter sales to rise sequentially by 6% to $254.3 million. The company had previously put first-quarter sales between $242.3 million and $247.1 million, and Wall Street analysts had been expecting sales of $245 million, on average. The company didn't offer earnings guidance. The Thomson First Call consensus is 13 cents a share. Altera added 6 cents to $20.43 Thursday morning.


( NTOP) reported preliminary second-quarter sales Wednesday that fell short of Wall Street estimates and said final results for the period will be delayed as it tries resolve some accounting issues. The company lost $8.6 million, or 11 cents a share, on sales of $20 million in the period. While Net2Phone didn't provide a profit figure that was comparable to analysts' estimate, the top line was about $2 million below forecasts. The company also said it had identified problems in the way it records various assets, including deferred revenue. The stock fell 46 cents to $2.03 Thursday morning.

Encysive Pharmaceuticals

( ENCY) announced plans Wednesday night to sell a $100 million convertible note to qualified institutional buyers in a Rule 144A private placement. Proceeds will be used to fund clinical development, marketing and launch preparations for its Thelin product and to research other drug candidates. The stock lost 38 cents to $9.66 Thursday morning.

Biotechnology company



said its fourth-quarter loss narrowed to $3.7 million, or 7 cents a share, from $5.2 million, or 10 cents a share, last year. Revenue rose 25% from a year ago to $3 million, boosted by increased funding for its HIV and malaria vaccine programs. Analyst surveyed by Thomson First Call had been forecasting a loss of 9 cents a share on sales of $3.3 million. Shares gained 11 cents to $1.85 Thursday.